Rosetta Genomics, a promoter Based in Philadelphia of microRNA-based molecular diagnostic tests, developed an exam of the diagnosis of the complete mesothelioma that is now commercially available. Is the test the third test diagnoses microRNA-based created by the lab and is known like miRview? meso.

The test now represents one of the exams diagnose the most exact available in the differentiation of cancers different of the lung. The medical community has enthusiastic therefore far about to incorporate the test in his established diagnostic procedures.

"I am very excited to see a test finally molecularly based that can differentiate mesothelioma of several types of carcinomas objectively in the lung with such high level of accurateness" says Harvey Pass, MD, Thoracic Surgery Chief and Thoracic Oncology in the university of New York Medical Langone Centre.

Mesothelioma is an aggressive malignancy that occurs in the interior coating of the lung and other internal organs. Mesothelioma is known how to be caused only by exhibition to asbestos, a fibrous mineral that has been included in the compounds of the construction and the industrial matters of the isolation. Before the development of the current test, there were few paths to eliminate mesothelioma conclusively, in particular among this known have been exposed to asbestos.

Early diagnosis and clear identification of cancers of the lung and mesothelioma are important to identify options of the treatment for the patients. The regimes of the treatment differ in cancer of the lung and sick of the mesothelioma and conclusive identification of the malignancy will now allow the doctors to prescribe options of the faster treatment and more efficiently.

---

Add this page to your favorite Social Bookmarking websites